GENE ONLINE|News &
Opinion
Blog

2021-07-13| Asia-PacificCOVID-19

COVID-19: Foxconn and TSMC Closes Deal to Secure 10 Million Pfizer Vaccines for Taiwan

by Tyler Chen
Share To

Taiwan has been a good model for battling the COVID-19 pandemic, with one of the lowest infected cases and deaths worldwide. But lately, the country has faced a spike in numbers, going into level 3 restriction for weeks. The best strategy to control the virus spread would be to vaccinate a majority of the population quickly. To do that, the country must have enough vaccine doses.

 

Foxconn and TSMC Seal the Deal

On July 12th, Taiwanese tech giants Foxconn and TSMC announced completing the purchase of 10 million doses of Pfizer/BioNTech’s COVID-19 vaccine, BNT162b2. The vaccines will be shipped to Taiwan as early as September. By then, all the vaccines will be donated to the government and will be distributed by Taiwan’s CDC to execute the mass inoculation strategy.

Details of the delivery timeframe are not disclosed. However, the total cost of the acquisition is around $350 million, with TSMC and Foxconn each spending $175 million for acquiring 5 million doses of BNT162b2.

In order to acquire the vaccine, they had to make deals with China’s Shanghai Fosun Pharmaceutical, which holds the right to sell BNT162b2 in China, Hong Kong, Macao, and Taiwan. In May, Taiwan had accused China of interfering with their access to BNT162b2, but China had denied those claims.

 

Has Taiwan Procured Enough COVID-19 Vaccines?

Currently, Taiwan has vaccinated 3.5 million citizens with at least one shot of COVID-19 vaccines, at an inoculation rate of 14.66%. It has purchased around 39 million doses, which is enough to reach herd immunity for the country. However, the time of delivery would play a huge part in quickly establishing protection since the Delta variant was detected in Taiwan at the beginning of June.

So far, Taiwan has acquired vaccines from AstraZeneca, Moderna, and Pfizer/BioNTech. In addition, it is counting on two of its domestic drugmakers, Medigen and United Biomedical, whose vaccines are just inching toward Phase 3 clinical trials.

Among the 39 million doses that it now has, around 5.8 million have come from donations made by Japan (3.3 million AZ vaccines), the United States (2.5 million Moderna vaccines), and Lithuania (20,000 AZ vaccines).

Related Article: Korea Receives 700,000 COVID-19 Vaccines from Israel Under a Swap Deal

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
Micronbrane Medical Aspires to Further Clinical Collaboration Following the Successful Series A Funding
2022-12-01
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!